The questionnaire for HITS-API was primarily that used nationally for HITS in 2000. Participants were recruited from three populations at highest risk for HIV (cialis professional treating HIV infection when used in combination with other medicines) men who have sex with men (MSM) who have had sexual contact with other men in the past 12 months; higher-risk heterosexuals (HRH) who had two or more opposite sex partners in the past 12 months; and injection drug users (IDU) who had injected in the past 12 months. The eligibility requirements for both studies included being >18 years of age, a resident of Washington State for at least six months, English speaking and meeting the risk criteria (MSM, IDU and/or HRH, as above). HITS-API also required subjects to self-identify as APIs. Formative research was conducted to select venues for both projects and to identify other recruitment methods for HITS-API, including advertising, use of outreach workers and respondent-driven sampling (RDS). All participants provided informed consent prior to the interview. Trained staff conducted the interviews and respondents received monetary incentive for participation. Analyses were done using SAS v.8.2 software (Cary, NC, 1999-2001). Survey methods were reviewed and approved by CDC and Washington State Institutional Review Boards.
Data from HITS-2000 and HITS-API were compared to see whether there were differences between the at-risk API population and a more racially/ethnically diverse cross-section of at-risk populations in Seattle and King County. If participants met criteria for more than one risk group, a hierarchy of risk behavior was used in assigning the participant to a risk group: MSM, then IDU, followed by HRH. Unsafe behaviors were defined as sex with nonpri-mary partners in the past year where condoms were not always used, or sharing needles or equipment for injection drug use in the past year. Statistical analyses included Chi-squares and relative risks (RR) with 95% confidence intervals (95% CI) to measure the strength of associations. lansoprazole 30 mg